Mark Weinberger - Johnson Johnson Independent Director

<div class='circular--portrait' style='background:#4E8BFC;color: #ffffff;font-size:4em;padding-top: 25px;;'>JJ</div>
JNJ -- USA Stock  

 Earnings Call  This Week

  Director
We currently do not have informatin regarding Mark Weinberger. This executive tanure with Johnson Johnson is not currenlty determined.
Age: 57  Director Since 2019      
732 214-0332  www.jnj.com

Mark Weinberger Latest Insider Activity

Johnson Johnson Management Efficiency

Johnson Johnson has Return on Asset of 8.83 % which means that on every $100 spent on asset it made $8.83 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 28.55 %, implying that it generated $28.55 on every 100 dollars invested. Johnson Johnson management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. Johnson Johnson Return on Investment is decreasing as compared to previous years. The last year's value of Return on Investment was reported at 19.14. The current Return on Average Assets is estimated to increase to 0.009237, while Return on Invested Capital is estimated to decrease to 0.29. Johnson Johnson Net Current Assets as percentage of Total Assets are decreasing as compared to previous years. The last year's value of Net Current Assets as percentage of Total Assets was reported at 7.98. The current Return on Average Assets is estimated to increase to 0.009237, while Tax Assets are estimated to decrease to under 6.8 B. Johnson Johnson Current Liabilities is increasing as compared to previous years. The last year's value of Current Liabilities was reported at 30.54 Billion. The current Tax Liabilities is estimated to increase to about 20.2 B, while Total Liabilities is estimated to decrease to under 90.3 B.
The company has 27.58 B in debt with debt to equity (D/E) ratio of 0.45, which is OK given its current industry classification. Johnson Johnson has a current ratio of 1.28, demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Nicholas MooreGilead Sciences
2004
Alan LacyBristol Myers Squibb
2008
Theodore SamuelsBristol Myers Squibb
2017
Antonio ParesGrifols S A
2014
Juan LucianoEli Lilly And
2019
Deryck MaughanGlaxoSmithKline PLC
2013
Vindi BangaGlaxoSmithKline PLC
2017
Harish ManwaniGilead Sciences
2018
Michael GrobsteinBristol Myers Squibb
2007
Julia HallerBristol Myers Squibb
2019
Dinesh PaliwalBristol Myers Squibb
2013
Gayle WilsonGilead Sciences
2001
Stephen WrightGW Pharmaceuticals Plc
2005
Adam GeorgeGW Pharmaceuticals Plc
2012
Gerald StorchBristol Myers Squibb
2012
Kevin LoftonGilead Sciences
2009
Ralph AlvarezEli Lilly And
2009
Jose BaselgaBristol Myers Squibb
2018
Manvinder BangaGlaxoSmithKline PLC
2016
Judy LewentGlaxoSmithKline PLC
2011
Sherilyn McCoyAstrazeneca PLC
2017

Company Summary

Johnson Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. The company was founded in 1886 and is based in New Brunswick, New Jersey. Johnson Johnson operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 132200 people.Johnson Johnson (JNJ) is traded on BATS Exchange in USA. It is located in One Johnson and Johnson Plaza, New Brunswick, NJ 08933, United States and employs 132,200 people. Johnson Johnson is listed under Pharmaceutical Products category by Fama And French industry classification.

Johnson Johnson Leadership Team

A Washington, Independent Director
Jennifer Doudna, Independent Director
Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee
William Perez, Independent Director
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer
Marillyn Hewson, Independent Director
Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer
Mary Coleman, Independent Director
Michael Ullmann, VP, General Counsel and Member of Executive Committee
Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals
Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer
Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals
Mary Beckerle, Independent Director
Sandra Peterson, Group Worldwide Chairman and Member of Executive Committee
Scott Davis, Director
Louise Mehrotra, Vice President Investor Relations
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices
Ronald Williams, Independent Director
Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer
D Davis, Independent Director
Hubert Joly, Independent Director
Anne Mulcahy, Lead Independent Director
Joseph Wolk, Chief Financial Officer, Executive Vice President
Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer
Ian Davis, Independent Director
Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee
Mark McClellan, Independent Director
Charles Prince, Independent Director
Eugene Washington, Independent Director
Dominic Caruso, CFO, VP of Fin. and Member of Executive Committee
Peter Fasolo, Chief Human Resource Officer, Executive Vice President
Susan Lindquist, Independent Director
Mark Weinberger, Independent Director

Stock Performance Indicators

Did you try this?

Run Idea Analyzer Now

   

Idea Analyzer

Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Please also try Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page